ASSOCIATION OF ALZHEIMER DISEASE PATHOLOGY WITH ABNORMAL LIPID METABOLISM: THE HISAYAMA STUDY

Gerson T. Lesser, Bronx, NY: Matsuzaki et al. noted associations of total serum cholesterol (TC) and low-density lipoprotein (LDL) with frequency of neuritic plaques (NP) but not with neurofibrillary tangles (NFT). In a WriteClick submission, Mascitelli et al. note that these results are “inconsistent with other studies.” Relatively few lipid-Alzheimer disease (AD) investigations are similarly neuropathologically based. Among these, Matsuzaki et al. and Mascitelli et al. may not be aware of the publications of Kuo et al. and of our group. Both of our findings supported the Hisayama findings and presented evidence contrary to the comments of Mascitelli et al. In 2001, we found that nursing home residents with AD pathology (Consortium to Establish a Registry for Alzheimer’s Disease [CERAD]) had significantly higher TC and LDL than residents with dementia with other-than-AD pathology. This was later confirmed in a larger nursing home cohort, additionally showing that increasing certainty of AD (CERAD-based) and increasing counts of NP were each significantly associated with higher levels of TC and LDL. We further confirmed the finding of Matsuzaki et al. of no significant lipid–NFT correlations. Our data also conflict with the suggestion by Mascitelli et al. that the results of Matsuzaki et al. might be confounded by statin use; only 6% of our subjects had used statins and, when adjusted for statin use, the lipid–NP relationships were unchanged.

Copyright © 2012 by AAN Enterprises, Inc.


THROMBOMODULIN AND THE BRAIN: PAST, PRESENT, AND FUTURE

Daniel A. Lawrence, Enming J. Su, Ann Arbor, MI; Karl-Uwe Petersen, Aachen, Germany: The recent Editorial by Dr. Fisher discussed the findings of Giwa et al. and emphasized that, currently, the anticoagulant thrombomodulin (TM) “is not commonly discussed within neurologic circles,” but that it may have significant advantages over other anticoagulants in the setting of ischemic stroke. We could not agree more with Dr. Fisher’s assessment and would like to point out two recent studies demonstrating the efficacy and safety of recombinant soluble TM in two independent animal models of ischemic stroke. These studies were performed by different laboratories and carried out in different species, with 2 very different model paradigms. Su et al. (see also...
Association of Alzheimer Disease Pathology with Abnormal Lipid Metabolism: The Hisayama Study

Gerson T. Lesser

Neurology 2012;78;1280
DOI 10.1212/WNL.0b013e318254f6ad

This information is current as of April 16, 2012

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/78/16/1280.1.full

References
This article cites 5 articles, 2 of which you can access for free at:
http://n.neurology.org/content/78/16/1280.1.full#ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise